MX2024001889A - Compuestos deuterados. - Google Patents
Compuestos deuterados.Info
- Publication number
- MX2024001889A MX2024001889A MX2024001889A MX2024001889A MX2024001889A MX 2024001889 A MX2024001889 A MX 2024001889A MX 2024001889 A MX2024001889 A MX 2024001889A MX 2024001889 A MX2024001889 A MX 2024001889A MX 2024001889 A MX2024001889 A MX 2024001889A
- Authority
- MX
- Mexico
- Prior art keywords
- deuterated compounds
- compounds
- deuterated
- formula
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021112521 | 2021-08-13 | ||
| CN2022106648 | 2022-07-20 | ||
| PCT/CN2022/111089 WO2023016440A1 (en) | 2021-08-13 | 2022-08-09 | Deuterated compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001889A true MX2024001889A (es) | 2024-02-29 |
Family
ID=85199822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001889A MX2024001889A (es) | 2021-08-13 | 2022-08-09 | Compuestos deuterados. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240270731A1 (https=) |
| EP (1) | EP4384507A4 (https=) |
| JP (1) | JP2024532807A (https=) |
| KR (1) | KR20240047401A (https=) |
| CN (1) | CN116848095B (https=) |
| AR (1) | AR126778A1 (https=) |
| CA (1) | CA3227149A1 (https=) |
| IL (1) | IL310176A (https=) |
| MX (1) | MX2024001889A (https=) |
| TW (1) | TW202320762A (https=) |
| WO (1) | WO2023016440A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118480034B (zh) * | 2023-02-13 | 2025-02-11 | 礼邦医药(香港)有限公司 | 氘代化合物的晶型或盐 |
| TW202547458A (zh) * | 2024-03-26 | 2025-12-16 | 香港商禮邦醫藥(香港)有限公司 | 用於治療體染色體顯性多囊性腎病之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60211891T2 (de) * | 2001-05-15 | 2007-05-24 | F. Hoffmann-La Roche Ag | Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes |
| US7262303B2 (en) * | 2003-09-29 | 2007-08-28 | Hoffman-La Roche Inc. | Process for the production of chiral propionic acid derivatives |
| JP7618384B2 (ja) * | 2017-02-21 | 2025-01-21 | ジェンフィ | Pparアゴニストとfxrアゴニストとの組合せ |
| CN109265380A (zh) * | 2017-10-18 | 2019-01-25 | 深圳市塔吉瑞生物医药有限公司 | 取代的丙-2-烯-1-酮化合物及其药物组合物 |
| WO2020156683A1 (en) * | 2019-02-01 | 2020-08-06 | F. Hoffmann-La Roche Ag | Aleglitazar for use in the treatment or prevention of major adverse cardiac events |
| CN112209896B (zh) * | 2019-07-10 | 2023-05-16 | 苏州泽璟生物制药股份有限公司 | 噻唑烷二酮衍生物以及包含其的药物组合物 |
| CN118480034B (zh) * | 2023-02-13 | 2025-02-11 | 礼邦医药(香港)有限公司 | 氘代化合物的晶型或盐 |
-
2022
- 2022-08-09 TW TW111129796A patent/TW202320762A/zh unknown
- 2022-08-09 JP JP2024508768A patent/JP2024532807A/ja active Pending
- 2022-08-09 EP EP22855421.8A patent/EP4384507A4/en active Pending
- 2022-08-09 CA CA3227149A patent/CA3227149A1/en active Pending
- 2022-08-09 CN CN202280014488.6A patent/CN116848095B/zh active Active
- 2022-08-09 US US18/293,337 patent/US20240270731A1/en active Pending
- 2022-08-09 MX MX2024001889A patent/MX2024001889A/es unknown
- 2022-08-09 IL IL310176A patent/IL310176A/en unknown
- 2022-08-09 WO PCT/CN2022/111089 patent/WO2023016440A1/en not_active Ceased
- 2022-08-09 KR KR1020247007871A patent/KR20240047401A/ko active Pending
- 2022-08-12 AR ARP220102177A patent/AR126778A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202320762A (zh) | 2023-06-01 |
| CA3227149A1 (en) | 2023-02-16 |
| AR126778A1 (es) | 2023-11-15 |
| US20240270731A1 (en) | 2024-08-15 |
| EP4384507A4 (en) | 2025-06-18 |
| CN116848095A (zh) | 2023-10-03 |
| EP4384507A1 (en) | 2024-06-19 |
| JP2024532807A (ja) | 2024-09-10 |
| WO2023016440A1 (en) | 2023-02-16 |
| AU2022327461A1 (en) | 2024-02-01 |
| KR20240047401A (ko) | 2024-04-12 |
| CN116848095B (zh) | 2024-05-24 |
| IL310176A (en) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202005326B (en) | Heteroaryl compounds as type ii irak inhibitors and uses hereof | |
| ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
| PH12020500396A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof | |
| WO2021262826A3 (en) | 1'-cyano nucleoside analogs and uses thereof | |
| GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
| WO2018226622A8 (en) | Compounds for treating huntington's disease | |
| MX2024013464A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| ZA202006377B (en) | Boronic acid derivatives and therapeutic uses thereof | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| DE602004024213D1 (en) | Aminopropanolderivate | |
| MX2022012239A (es) | Compuestos de amida y usos de los mismos. | |
| SA520411726B1 (ar) | مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه | |
| PH12022552177A1 (en) | Heteroaryl heterocyclic compounds and uses thereof | |
| MX2024001889A (es) | Compuestos deuterados. | |
| EP4643954A3 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| MX2020011986A (es) | Composiciones que comprenden glucosa y hemicelulosa y su uso. | |
| MX2024002872A (es) | Compuestos clorados de tetralina y composiciones farmaceuticas. | |
| MX2025012133A (es) | Derivados de tiadiazolona, composiciones y usos de estos | |
| MX2023010823A (es) | Degradadores selectivos del receptor de estrogeno. | |
| MX2023009190A (es) | Compuestos triciclicos y usos de los mismos. | |
| WO2021214348A3 (de) | Verbindungen für elektronische vorrichtungen | |
| ZA202401345B (en) | Polypeptide drug conjugate having novel structure and application thereof | |
| PH12021552779A1 (en) | Amorphous pi3k inhibitor and pharmaceutical composition comprising same | |
| MX2023001979A (es) | Compuestos de pirimidinona y usos de los mismos. |